News
Insights
Jobs
Career Advice
Companies
Hotbeds
More

SUBSCRIBE

SUBSCRIBE

News
Insights
Jobs
Career Advice
Companies
Hotbeds
More

Search Query

Search Results

Looking for jobs? Search jobs

18,291 Results

Type

Article (805)
Company Profile (2)
Press Release (17484)

Section

Business (5072)
Career Advice (2)
Deals (1066)
Drug Delivery (1)
Drug Development (2076)
Employer Resources (1)
FDA (380)
Job Trends (305)
News (8631)
Policy (761)

Tag

Date

Today (7)
Last 7 days (24)
Last 30 days (73)
Last 365 days (1008)
2024 (874)
2023 (1050)
2022 (2140)
2021 (1805)
2020 (1283)
2019 (967)
2018 (818)
2017 (1026)
2016 (1059)
2015 (1212)
2014 (826)
2013 (558)
2012 (731)
2011 (664)
2010 (607)

Location

Africa (9)
Arizona (3)
Asia (528)
Australia (161)
California (45)
Canada (18)
Connecticut (12)
Europe (6586)
Florida (11)
Illinois (2)
Maryland (15)
Massachusetts (70)
Michigan (2)
Nevada (10)
New Jersey (31)
New York (4)
North Carolina (5)
Northern California (26)
Pennsylvania (4)
South America (11)
Southern California (11)
Texas (9)
Virginia (2)

Filters

Type

Article (805)
Company Profile (2)
Press Release (17484)

Section

Business (5072)
Career Advice (2)
Deals (1066)
Drug Delivery (1)
Drug Development (2076)
Employer Resources (1)
FDA (380)
Job Trends (305)
News (8631)
Policy (761)

Tag

Date

Today (7)
Last 7 days (24)
Last 30 days (73)
Last 365 days (1008)
2024 (874)
2023 (1050)
2022 (2140)
2021 (1805)
2020 (1283)
2019 (967)
2018 (818)
2017 (1026)
2016 (1059)
2015 (1212)
2014 (826)
2013 (558)
2012 (731)
2011 (664)
2010 (607)

Location

Africa (9)
Arizona (3)
Asia (528)
Australia (161)
California (45)
Canada (18)
Connecticut (12)
Europe (6586)
Florida (11)
Illinois (2)
Maryland (15)
Massachusetts (70)
Michigan (2)
Nevada (10)
New Jersey (31)
New York (4)
North Carolina (5)
Northern California (26)
Pennsylvania (4)
South America (11)
Southern California (11)
Texas (9)
Virginia (2)

18,291 Results for "wolters kluwer nv".

Sort By

Press Releases

QIAGEN N.V. to release results for Q3 2024 and hold webcast

October 10, 2024
·
1 min read
Pharm Country

Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect

NanoViricides, Inc. reports that its clinical stage lead nanoviricide broad-spectrum antiviral drug candidate, NV-387, results in an ideal flat blood concentration profile for an extended time period upon oral administration in two different animal models.

June 11, 2024
·
9 min read
Pharm Country

Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure

NanoViricides, Inc., a global leader in broad-spectrum antiviral nanomedicines, says that the strong antiviral activity of NV-387 against RSV/A2 is clearly demonstrated by lungs remaining normal and showing no infection-related damage, when treated orally with NV-387, in a lethal lung RSV infection animal model.

May 20, 2024
·
7 min read
QIAGEN N.V. to release results for Q1 2024 and hold webcast

QIAGEN N.V. announced plans to release results for the first quarter 2024.

April 9, 2024
·
1 min read
Pharm Country

The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect

NanoViricides, Inc. reports on the highly desirable blood concentration profile of its lead clinical stage broad-spectrum antiviral agent NV-387 upon intravenous administration in a non-human primate animal model.

June 4, 2024
·
8 min read
Genetown

Merus N.V. Announces Proposed Public Offering of Common Shares - May 28, 2024

Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced the launch of a proposed underwritten public offering of $300,000,000 of its common shares.

May 28, 2024
·
10 min read
Drug Development

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model

NanoViricides, Inc. reports that the ultra-broad-spectrum antiviral NV-387, a clinical Phase II stage drug candidate, was found to be effective in protecting lungs from damage in a lethally infected Influenza A H3N2 mouse model.

June 20, 2024
·
10 min read
Press Releases

Press Release Biocartis NV: Biocartis announces six Idylla™ abstracts to be presented at AMP 2024 Annual Meeting

October 23, 2024
·
6 min read
Press Releases

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID

October 1, 2024
·
11 min read
Pharm Country

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides

NanoViricides, Inc., a clinical stage global leader in broad-spectrum antiviral nanomedicines, comments that the ultra-broad-spectrum antiviral NV-387 could be an important weapon against bird flu H5N1 viruses.

June 24, 2024
·
8 min read

1 of 1,830

BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.

Explore
About
More

© 1985 - 2024 BioSpace.com. All rights reserved.

twitter
instagram
facebook
linkedin